La vendita allo scoperto per AdvisorShares Psychedelics ETF dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di AdvisorShares Psychedelics ETF. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

AdvisorShares Psychedelics ETF (ARCA:PSIL), Report sulle vendite allo scoperto

AdvisorShares Psychedelics ETF

Healthcare

Other

The Fund is an actively managed exchange-traded fund (ETF) that seeks to achieve its investment objective by investing, under normal circumstances, at least 80% of its net assets (plus any borrowings for investment purposes) in (i) securities of companies that derive at least 50% of their net revenue from or devote 50% of their assets to psychedelic drugs and (ii) derivatives that have economic characteristics similar to such securities. The Fund primarily invests in publicly listed life sciences companies focused on psychedelic medicines as well as other companies with activities in the psychedelics business. The Fund invests in exchange-listed equity securities, including common and preferred stock of U.S. and foreign mid, small and micro-capitalization companies, and in total return swaps intended to provide exposure to such companies.

Mind Medicine Mindmed Inc

Compass Pathways Plc Adr

Gh Research Plc

NRX Pharmaceuticals Inc.

Intra-Cellular Therapies Inc

Atai Life Sciences BV

Alkermes Plc

Vistagen Therapeutics Inc.

ADVISORSHARES PSYCHEDELICS ETF

Psychedelics

Broad U.S. Equity ETFs

Markets

ETFs

AMZN

GOOGL

NERD

PLTR

PLTU

PSIL

RBLX

SIXG

TTWO

In un contesto di incertezza economica, alcuni fondi di investimento hanno dimostrato una notevole resilienza.

Turbolenze di mercato? No problem: 5 ETF che hanno guadagnato bene la scorsa settimana

Red Cat Hldgs's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCAT#NYSE">RCAT</a>) short percent of float has risen 45.9% since its last report. The company recently reported that it has 12.33 million shares sold short, which is 18.34% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.17 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock/">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest">List of the most shorted stocks</a>
<h3>Red Cat Hldgs Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739283338_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Red Cat Hldgs has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Red Cat Hldgs's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://pro.benzinga.com/">Benzinga Pro</a>, Red Cat Hldgs's peer group average for short interest as a percentage of float is 7.35%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze/">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

RCAT

Peering Into Red Cat Hldgs's Recent Short Interest

The blockbuster trade that sent Luka Doncic to the Los Angeles Lakers cost him a potential record-breaking contract extension, but NBA salary rules could still lead to an even bigger payday.
Doncic&#8217;s move from Dallas last week means he can&#8217;t sign a five-year, $345 million supermax extension this summer. Instead, his immediate options max out at four years and $229 million with the Lakers, <a href="https://www.cnbc.com/2025/02/06/luka-doncic-misses-out-on-supermax-contract-but-could-make-even-more.html">according to CNBC</a>.
However, NBA salary cap expert Bobby Marks identified a lucrative alternative path to CNBC. If Doncic signs a shorter deal this offseason, he could become eligible for a contract worth nearly $420 million when he reaches 10 years of service time.
Don't Miss:
<ul>
<li>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a></li>
<li>They call it the &#8216;Biggest Disruption To IP Since Disney&#8217; and their funding window is closing. <a href="https://www.benzinga.com/money/elf-labs-1">Less than 48 hours left  for investors to claim shares at just $2/share with $980 minimum.</a></li>
</ul>
The financial implications move beyond contract values. Moving from Texas to California means Doncic faces much higher state income taxes, as Texas has no state income tax while California maintains the nation&#8217;s highest rate.
The trade reshaped both teams&#8217; salary structures. Anthony Davis, heading to Dallas, is locked into a three-year, $186 million extension through at least 2026-27, with a player option worth nearly $63 million for 2027-28. Davis waived a $6 million trade kicker, partly due to Texas&#8217;s favorable tax environment, <a href="https://x.com/mcten/status/1886069335484932162">ESPN reported</a>.
Trending: Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> you can become an investor for $0.80 per share today.</a>
Doncic, 25, currently earns an average of $43 million annually on his five-year, $215 million deal. Had he stayed in Dallas, his next contract could have averaged $69 million per year, potentially reaching $78 million for the 2030-31 season.
The trade surprised the basketball world. The three-team deal sent Doncic, Maxi Kleber, and Markieff Morris to Los Angeles, while Dallas received Davis, Max Christie, and an unprotected 2029 first-round pick.
Doncic who averages 28.6 points, 8.7 rebounds, and 8.3 assists for his career, the move could mean sacrificing short-term earnings for long-term potential.
See Also: According to Juniper Research, the total value of B2B cross-border payments stored on the blockchain is projected to exceed $4.4 trillion — <a href="https://www.benzinga.com/money/web3-enabler-future-of-enterprise-transactions">Join the first company to bring blockchain payments to Salesforce early with just $100.</a>
The deal&#8217;s timing could affect more than just Doncic&#8217;s earnings. Reports of <a href="https://www.benzinga.com/general/sports/25/02/43446178/mark-cuban-once-said-hed-pick-luka-over-his-wife-now-fans-rage-over-trade-to-lakers">tension in Dallas came after the deal</a>, but Doncic maintained professionalism. &#8220;I would say I always take the high road. I had my amazing moments in Dallas with all my teammates, coaches and most importantly the fans,&#8221; he told ESPN. &#8220;They always supported me, and it was an amazing journey.&#8221;
The move also points to broader NBA salary trends, as teams navigate the league&#8217;s increasingly complex cap rules. Players reaching 10 years of service can command up to 35% of a team&#8217;s salary cap, a threshold Doncic will hit just as the NBA&#8217;s new media rights deal is expected to dramatically increase team revenues.
Read Next:
<ul>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
<li>Built on the trusted network of Fortune 500 companies, <a href="https://www.benzinga.com/money/web3-enabler-the-most-boring-blockchain-company-partners-with-salesforce">this blockchain company partners with Salesforce to uproot lengthy and expensive B2B transactions, and you can invest with just $100. </a></li>
</ul>

Startups

Nearly $420 Million—How Luka Doncic Could Still Cash In Despite Trade Setback

B. Riley Securities analyst Craig Ellis maintains ON Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ON#NASDAQ">ON</a>) with a Buy and lowers the price target from $90 to $73.

News

Price Target

Analyst Ratings

B. Riley Securities Maintains Buy on ON Semiconductor, Lowers Price Target to $73

Keybanc analyst Eric Heath maintains Okta (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OKTA#NASDAQ">OKTA</a>) with a Overweight and raises the price target from $115 to $125.

OKTA

Keybanc Maintains Overweight on Okta, Raises Price Target to $125

B. Riley Securities analyst Craig Ellis maintains Amkor Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMKR#NASDAQ">AMKR</a>) with a Buy and lowers the price target from $38 to $32.

AMKR

B. Riley Securities Maintains Buy on Amkor Tech, Lowers Price Target to $32

McDonald&#8217;s Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCD#NYSE">MCD</a>) reported in-line earnings for its <a href="https://www.benzinga.com/quote/MCD/earnings">fourth quarter on Monday</a>.
The company reported a fourth-quarter sales decline of 0.3% year-on-year to $6.388 billion, missing the analyst consensus estimate of $6.442 billion. Adjusted EPS of $2.83 was in line with the analyst consensus estimate.
Global comparable sales increased 0.4%, while U.S. comparable sales slipped 1.4%. Comparable sales for International Operated Markets segment increased 0.1% and the International Developmental Licensed Markets segment improved 4.1%.
"Accelerating the Arches continues to be the right strategy as we focus on growing market share," said CEO Chris Kempczinski. "We're playing to win, focusing on our customers with outstanding value, exciting menu innovation and culturally relevant marketing."
McDonald&#8217;s shares gained 4.8% to close at $308.42 on Monday.
These analysts made changes to their price targets on McDonald&#8217;s following earnings announcement.
<ul>
<li>Wedbush analyst Nick Setyan maintained McDonald&#8217;s with an Outperform and raised the price target from $320 to $330.</li>
<li>Citigroup analyst Jon Tower maintained McDonald&#8217;s with a Buy and raised the price target from $336 to $360.</li>
<li>Baird analyst David Tarantino maintained the stock with a Neutral and raised the price target from $305 to $310.</li>
<li>JP Morgan analyst John Ivankoe maintained McDonald&#8217;s with an Overweight and boosted the price target from $280 to $300.</li>
</ul>
Considering buying MCD stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="501" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11091022/image-95-1024x501.png" alt="" class="wp-image-776646" style="width:554px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11091022/image-95-1024x501.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11091022/image-95-300x147.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11091022/image-95-768x375.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11091022/image-95.png 1078w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next:
<ul>
<li> <a href="https://www.benzinga.com/25/02/43592071/top-3-tech-stocks-that-may-jump-this-month">Top 3 Tech Stocks That May Jump This Month</a></li>
</ul>

These Analysts Boost Their Forecasts On McDonald's After Q4 Earnings

LAES

SEALSQ Accelerating Cybersecurity Transformation Of Unmanned Aerial Systems Through Secure Microcontrollers.

Keybanc analyst Eric Heath maintains Palo Alto Networks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PANW#NASDAQ">PANW</a>) with a Overweight and raises the price target from $217 to $240.

PANW

Keybanc Maintains Overweight on Palo Alto Networks, Raises Price Target to $240

GlobalFoundries Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GFS#NASDAQ">GFS</a>) reported a fiscal fourth-quarter 2024 revenue decline of 1% year-on-year to $1.830 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/g43618818/globalfoundries-reports-fourth-quarter-2024-and-fiscal-year-2024-financial-results" rel="noreferrer noopener">analyst consensus estimate of $1.829 billion</a>.
The contract chipmaker&#8217;s adjusted EPS of 46 cents beat the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">analyst consensus estimate of 44 cents</a>.&nbsp;The stock price declined after the report.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/25/02/43540659/arms-rising-royalties-and-v9-adoption-strengthen-market-position-analysts-say" rel="noreferrer noopener">Arm&#8217;s Rising Royalties and v9 Adoption Strengthen Market Position, Analysts Say</a>
Smart mobile device revenue declined 4% from a year ago <a target="_blank" href="https://investors.gf.com/financials-and-filings/quarterly-results" rel="noreferrer noopener">to&nbsp;$738 million</a>.
Communications infrastructure &amp; data center revenue grew 18% Y/Y to $170 million. Home and industrial IOT revenue decreased 13% Y/Y to $355 million. Automotive revenue rose 30% Y/Y to $414 million. Non wafer revenue slid 31% Y/Y to $153 million.
Margins: The adjusted gross margin declined by 360 bps to 25.4%, and the adjusted operating margin decreased by 510 bps to 15.6% due to pricing pressure. The adjusted EBITDA margin declined by 560 bps Y/Y to 36.1%.&nbsp;
As of December 31, 2024, GlobalFoundries generated $457 million in operating cash flow and held $4.2 billion in cash and equivalents.
CEO Dr. Thomas Caulfield noted adjusted guidance estimates during the quarter. He also highlighted 2024&#8217;s unique challenges for the industry, despite which it delivered over $1 billion of adjusted free cash flow. Caulfield expressed optimism over strong design win momentum across its end markets and product portfolio.
The company recorded a $935 million impairment charge related to legacy investments in production capacity at its Malta, New York facility. The company announced its <a target="_blank" href="https://www.benzinga.com/trading-ideas/movers/25/01/43063695/whats-going-on-with-globalfoundries-stock-friday" rel="noreferrer noopener">plans to develop</a> a center for advanced packaging and test capabilities at its Malta, New York facility to help meet the growing demand for U.S.-made essential chips used in AI, automotive, aerospace and defense, and communications applications.
Outlook: GlobalFoundries expects first-quarter revenue of $1.55 billion—$1.60 billion versus the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/guidance" rel="noreferrer noopener">$1.66 billion estimate</a>. The company expects adjusted EPS of $0.24-$0.34 versus&nbsp;the&nbsp;$0.32 estimate.
GlobalFoundries stock lost over 32% in value in the last 12 months. In the third quarter of 2024, the company held a <a href="https://www.benzinga.com/media/25/01/42981814/apple-and-nvidia-supplier-taiwan-semiconductor-leads-semiconductor-market-with-64-share" target="_blank" rel="noreferrer noopener">5% market share</a> in the global foundry business, backed by demand in the Internet of Things and communications infrastructure markets.
Price Action:&nbsp;GFS stock is down 7.23% at $35.01 premarket at the last check on Tuesday.
Also Read:
<ul>
<li><a href="https://www.benzinga.com/25/02/43541019/chip-equipment-stocks-gain-traction-as-ai-demand-tsmcs-capex-and-semiconductor-expansion-drive-valuations" target="_blank" rel="noreferrer noopener">Chip Equipment Stocks Gain Traction as AI Demand, TSMC&#8217;s Capex, and Semiconductor Expansion Drive Valuations</a></li>
</ul>
Photo Courtesy Of GlobalFoundries

Earnings

Guidance

Movers

Tech

GlobalFoundries Q4 Earnings: Revenue And EPS Beat, Margins Shrink, Revenue Outlook Disappoints Street

WIIM

DOMH

Dominari Holdings shares are trading higher after the company announced a $13.5 million registered direct and private placement. The company also added Donald Trump Jr. and Eric Trump to its advisory board.

Coca-Cola CFO Says Expect Modest Expansion At The Gross Margin Line For 2025 On Commodities Pressure

Retail Sales

LGMK

LogicMark Launches The Next Generation Of Guardian Alert 911 Plus

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the utilities sector.
<h3 class="wp-block-heading">The AES Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AES#NYSE">AES</a>)</h3>
<ul>
<li>Dividend Yield: 6.42%</li>
<li>Barclays analyst Nicholas Campanella maintained an Overweight rating and cut the price target from $17 to $12 on Jan. 27, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Mizuho analyst Anthony Crowdell maintained an Outperform rating and slashed the price target from $24 to $16 on Nov. 21, 2024. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: AES will host a conference call on Friday, Feb. 28, to review its fourth quarter and full year 2024 financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1">latest AES news</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="926" height="831" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11044452/image-89.png" alt="" class="wp-image-776181" style="width:484px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11044452/image-89.png 926w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11044452/image-89-300x269.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11044452/image-89-768x689.png 768w" sizes="(max-width: 926px) 100vw, 926px" /></a></figure>
<h3 class="wp-block-heading">Portland General Electric Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/POR#NYSE">POR</a>)</h3>
<ul>
<li>Dividend Yield: 4.86%</li>
<li>Jefferies analyst Julien Dumoulin-Smith maintained a Hold rating and cut the price target from $47 to $42 on Jan. 28, 2025. This analyst has an accuracy rate of 65%.</li>
<li>Barclays analyst Nicholas Campanella maintained an Equal-Weight rating and lowered the price target from $48 to $42 on Jan. 27, 2025. This analyst has an accuracy rate of 62%.</li>
<li>Recent News: Portland General Electric will host an analyst conference call and webcast on Friday, Feb. 14, to review its fourth quarter financial results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1">POR new</a>s </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="907" height="847" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11044528/image-90.png" alt="" class="wp-image-776183" style="width:585px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11044528/image-90.png 907w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11044528/image-90-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11044528/image-90-768x717.png 768w" sizes="(max-width: 907px) 100vw, 907px" /></a></figure>
<h3 class="wp-block-heading">Northwest Natural Holding Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NWN#NYSE">NWN</a>)</h3>
<ul>
<li>Dividend Yield: 4.90%</li>
<li>Stifel analyst Selman Akyol maintained a Buy rating and cut the price target from $45 to $44 on Nov. 14, 2024. This analyst has an accuracy rate of 71%.</li>
<li>Janney Montgomery analyst Michael Gaugler upgraded the stock from Neutral to Buy and raised the price target from $36 to $43 on Aug. 5, 2024. This analyst has an accuracy rate of 72%.</li>
<li>Recent News: On Feb. 10, Northwest Natural Holding hired Megan H. Berge as the company&#8217;s deputy general counsel and corporate secretary, and general counsel of NW Natural Gas Company, effective March 3.</li>
<li>Benzinga Pro&#8217;s real-time newsfeed alerted to latest <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1">NWN news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent021125&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="901" height="826" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11044553/image-2-24.png" alt="" class="wp-image-776184" style="width:507px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11044553/image-2-24.png 901w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11044553/image-2-24-300x275.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/02/11044553/image-2-24-768x704.png 768w" sizes="(max-width: 901px) 100vw, 901px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/25/02/43592071/top-3-tech-stocks-that-may-jump-this-month">Top 3 Tech Stocks That May Jump This Month</a></li>
</ul>

Pre-Market Outlook

Wall Street's Most Accurate Analysts Spotlight On 3 Utilities Stocks Delivering High-Dividend Yields

B. Riley Securities analyst Lucas Pipes maintains AZZ (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZZ#NYSE">AZZ</a>) with a Buy and raises the price target from $99 to $111.

B. Riley Securities Maintains Buy on AZZ, Raises Price Target to $111

Dominari Holdings Inc Shares Resume

Events

SHOP

Shopify CFO Says Q1 Operating Expenses Guide Of 41-42% Of Revenues Reflects A 500 To 600 Basis Point Improvement From Q1 Last Year

JP Morgan analyst Samik Chatterjee maintains LKQ (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>) with a Overweight and lowers the price target from $50 to $48.

JP Morgan Maintains Overweight on LKQ, Lowers Price Target to $48

SOS Enters Into Strategic Partnership Framework Agreement With Lepu Sodium Power To Optimize Electricity Use

THRY

Thryv And 1-800Accountant Enter Into Partnership Designed To Optimize Small Business Growth

Shopify CFO Says Expect The Move To 3-month Trials And Lack Of Substantive Pricing Changes In 2025 To Impact Subscription Solutions Growth

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
The New York Times published an article in early February about mental health and the failure of New York City to carefully <a href="https://www.nytimes.com/2024/02/08/nyregion/newyorktoday/mentally-ill-homeless.html">audit its program</a> to treat mentally ill people living on the streets. When I read articles like this, it makes me think about possible related investments. Specifically, in this case, mental health stocks.&nbsp;



It could be a drug company that&rsquo;s got a treatment for mental health that&rsquo;s working for patients. Another possibility is operators of mental health facilities. However, it would be false to say that I&rsquo;ve spent much time researching stocks in this niche area, so I&rsquo;m relatively unaware of the possibilities.



AdvisorShares <a href="https://advisorshares.com/etfs/psil/">launched</a> the AdvisorShares Psychedelics ETF (NYSEARCA:<a href="https://investorplace.com/stock-quotes/psil-stock-quote/">PSIL</a>) in September 2021. The shares could have done better, losing 85% of their value, trading around $1.50. PSIL invests in the emerging psychedelic drugs sector.&nbsp;



As someone who supports the Law Enforcement Action Partnership, which focuses on moving <a href="https://lawenforcementactionpartnership.org/about-us/mission-and-vision/">beyond the war on drugs</a>, I believe ETFs like PSIL are vital to supporting companies that are working to reduce the damage caused by addiction and poor mental health.&nbsp;&nbsp;



Unfortunately, PSIL hasn&rsquo;t met a better fate, but investing is about profits, not losses.&nbsp;



On the plus side, the holdings from PSIL gave me one of my three mental health stocks to buy to help change the world.&nbsp;&nbsp;



<h2>Bristol Myers Squibb (BMY)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/09/bmy1600b-300x169.jpg" alt="Bristol-Myers (BMY) logo at the top of a cellphone."><div>Source: Piotr Swat / Shutterstock.com</div></div>


Bristol Myers Squibb (NYSE:<a href="https://investorplace.com/stock-quotes/bmy-stock-quote/">BMY</a>) is the biggest of the three stocks.



In December, it <a href="https://news.bms.com/news/details/2023/Bristol-Myers-Squibb-Strengthens-Neuroscience-Portfolio-with-Acquisition-of-Karuna-Therapeutics/default.aspx">announced</a> the acquisition of Karuna Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/krtx-stock-quote/">KRTX</a>) for $14.0 billion, or $12.7 billion after cash. The $330 price per share is a 53% premium to Karuna&rsquo;s share price on Dec. 21, 2023.&nbsp;



Karuna is focused exclusively on developing medicines for people living with psychiatric and neurological conditions. The company&rsquo;s KarXT New Drug Application (NDA) for treating schizophrenia in adults was accepted by the Food and Drug Administration (FDA) for review by September 2024.&nbsp;&nbsp;



As Bristol Myers press release states, KarXT is in registrational trials both for adjunctive therapy to the existing standard of care agents in schizophrenia and for the treatment of psychosis in patients with Alzheimer&rsquo;s disease.



Bristol Myers is accelerating its participation in neuroscience. The acquisition of Karuna and KarXT should contribute significantly to the company&rsquo;s revenue growth in the second half of the 2020s and into the 2030s. Bristol Myers CEO Christopher Boerner stated:




&ldquo;This transaction fits squarely within our business development priorities of pursuing assets that are strategically aligned, scientifically sound, financially attractive, and have the potential to address areas of significant unmet medical need.&rdquo; 




<h2>Acadia Healthcare (ACHC)</h2>


<div><img width="300" height="165" src="https://investorplace.com/wp-content/uploads/2017/10/achcmsn-300x165.jpg" alt=""><div>Source: Shutterstock</div></div>


Acadia Healthcare (NASDAQ:<a href="https://investorplace.com/stock-quotes/achc-stock-quote/">ACHC</a>) was founded in <a href="https://www.acadiahealthcare.com/about/">Jan. 2005</a> in Franklin, TN. It provides psychiatric and chemical dependency services to its patients through inpatient psychiatric hospitals, specialty treatment facilities, residential treatment centers, outpatient clinics and therapeutic school-based programs.



The company operates <a href="https://www.acadiahealthcare.com/investors/">253 behavioral healthcare facilities</a> with approximately 11,100 beds in 39 states and Puerto Rico. It is the <a href="https://acadiahealthcare.gcs-web.com/static-files/61e71a13-989a-4493-a296-f8e936673b63">largest</a> behavioral health-focused provider in the country, treating roughly 75,000 people per day.&nbsp;



Approximately 51% of its $2.9 billion in trailing 12-month income through Sept. 30, 2023, is for acute care, followed by specialty (21%), comprehensive treatment centers (17%), and residential treatment centers (11%).



Its plan is three-fold: 1) grow the number of facilities through joint ventures and new builds, 2) expand its level of care for substance abuse disorders, and 3) leverage technology to improve patient care.&nbsp;



As U.S. Surgeon General Dr. Vivek Murthy pointed out in 2023, &ldquo;Mental health is the defining public health crisis of our time.&rdquo;



The company currently has 31 existing joint venture partnerships to accelerate facility growth.



Through Sept. 30, it had trailing 12-month adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) of $650 million, good for a 22.4% EBITDA margin.&nbsp;



I&rsquo;m very intrigued by Acadia&rsquo;s business.&nbsp;&nbsp;



<h2>Compass Pathways (CMPS)</h2>


<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/mnmd_mushrooms_1600-300x169.png" alt="Dried psilocybe cubensis psilocybin magic mushrooms inside and around a plastic prescription medicine bottle with no lid isolated on white background, Mind Medicine is in the psychedelic medicine business. MNMD stock"><div>Source: Daniel Patrick Martin / Shutterstock.com</div></div>


Compass Pathways (NASDAQ:<a href="https://investorplace.com/stock-quotes/cmps-stock-quote/">CMPS</a>) is the smallest of three mental health stocks with a market capitalization of $629 million. Its first major treatment is the use of COMP360 psilocybin, the <a href="https://compasspathways.com/about-us/">hallucinogenic chemical</a> obtained from certain types of mushrooms, for people with treatment-resistant depression.&nbsp;



In December, the company <a href="https://ir.compasspathways.com/news-releases/news-release-details/compass-pathways-announces-investigational-comp360-psilocybin">announced</a> that its phase 2 study of its investigational COMP360 psilocybin treatment was well received by people who have PTSD (post-traumatic stress disorder). There were no severe adverse effects on the 22 participants.&nbsp;Dr. Guy Goodwin, Chief Medical Officer, Compass Pathways, said:




&ldquo;Safety is of paramount importance when developing potential new treatments, so we are pleased to see these positive safety signals. These results are consistent with findings from other studies and add to the growing body of evidence to demonstrate the potential of COMP360 in difficult-to-treat mental health conditions.&rdquo; 




The company&rsquo;s <a href="https://finance.yahoo.com/news/wall-street-says-compass-pathways-120000983.html">phase 3 trial</a> is underway, with results expected in the summer and more by the middle of 2025.&nbsp;



Like most early-stage biotech firms, there are many expenses and no revenue. Compass is no different. Through the first nine months of 2023, it lost $98.5 million, about $20.3 million higher than a year earlier.&nbsp;



To keep the coffers full, it did a private placement in August that raised $125 million. If exercised, the warrants accompanying the American Depositary Shares (ADSs) would bring in an additional $160 million. With an exercise price of $9.93, the warrants are already in the money.&nbsp;



CMPS is the riskiest of the three. However, the potential reward is also relatively high if you&rsquo;re an aggressive investor.&nbsp;



On the date of publication, Will Ashworth did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com <a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">Publishing Guideline</a><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/">s</a>.
<div>Will Ashworth has written about investments full-time since 2008. Publications where he&rsquo;s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He particularly enjoys creating model portfolios that stand the test of time. He lives in Halifax, Nova Scotia.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
The post <a href="https://investorplace.com/2024/02/mental-health-mavericks-3-stocks-changing-the-game/">Mental Health Mavericks: 3 Stocks Changing the Game</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Mental Health Mavericks: 3 Stocks Changing the Game

Psychedelic therapy: FDA panel to review first ever MDMA-assisted PTSD treatment

Psychedelics Closer To Commercialization; Compass Far And Away The Leader

Psychedelic Stocks: Focus On Their Cash

ETFs&nbsp;(exchange-traded funds)&nbsp;are a cost-effective way to diversify a portfolio due to their low expense ratios compared to traditional mu...

Comments

AdvisorShares Psychedelics ETF

Vendite allo scoperto

AdvisorShares Psychedelics ETF (ARCA:PSIL), Report sulle vendite allo scoperto

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO